These findings demonstrate BC99’s capacity to attenuate multiple pathological pathways in allergic rhinitis (AR), including: IgA-mediated EOS activation and degranulation, Complement system activation via C3 reduction, and inflammatory cell recruitment through EOS suppression. The gene discussed is CD79A; the disease is allergic rhinitis.